top of page
Test Tubes


Exploiting cell cycle vulnerabilities to develop novel therapeutic strategies for ovarian cancer

Home: Welcome


Ovarian cancer is the fifth leading cause of female cancer-related death in the UK, accounting for over 4,000 UK deaths and ~185,000 deaths globally in 2018. The most prevalent subtype, high-grade serous ovarian carcinoma (HGSOC) is particularly lethal because it develops rapidly and often presents at an advanced stage. Treatment options are limited; typically, cytoreductive surgery and paclitaxel/platinum-based chemotherapy, maintenance therapy and hormone antagonists. While many patients initially respond well, most develop recurrent disease, yielding 10-year survival rates of about 35%. [More ...]



To explore novel therapeutic strategies, we are applying a multi-disciplinary approach focusing on several interconnected cell-cycle-related processes implicated in tumourigenesis, namely MYC overexpression, replication stress and aberrant mitoses. Our vision is that by generating new knowledge into the underlying biology of HGSOC we will be able to develop biomarker-driven strategies for patients with HR-proficient ovarian cancer. [More ...]

Scientist in the Lab


The current team consists of 12 scientists, including six research staff, four PhD students, one clinical fellow and a project manager, covering a broad range of skills including bioinformatics, DNA damage repair and cell division. Our research is underpinned by a living biobank, a growing collection of ex vivo cultures established from biopsies collected from patients being treated at the Christie Hospital. [More ...]

Home: Research


The Oglesby Cancer Research Building | Manchester Cancer Research Centre | Wilmslow Road | Manchester M20 4QL | United Kingdom

+44 161 306-0869

  • LinkedIn
Scientist on Tablet
Home: Contact
Home: Blog Feed
bottom of page